Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas

Cancer Research

Volumn 65, Issue 6, 2005, Pages 2260-2268

  Vance, Keith W ^a   Carreira, Suzanne ^a   Brosch, Gerald ^b   Goding, Colin M ^a  

^a MARIE CURIE RESEARCH INSTITUTE   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 1; HISTONE DEACETYLASE 1; PROTEIN P21; T BOX TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HETEROCHROMATIN; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; SENESCENCE; TBX 2 GENE; UPREGULATION;

ANIMALS; CELL AGING; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HETEROCHROMATIN; HISTONE DEACETYLASES; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; PROMOTER REGIONS (GENETICS); T-BOX DOMAIN PROTEINS;

EID: 16844387097     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3045     Document Type: Article

References (64)

1. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
2. Wynford-Thomas D. Cellular senescence and cancer. J Pathol 1999;187:100-11.
3. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
4. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003;113:703-16.
5. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
6. Bennett DC. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003;22: 3063-9.
7. Chin L, Merlino G, Depinho RA. Malignant melanoma: modern black plague and genetic black box. Genes Dev 1998;12:3467-81.
8. Sharpless E, Chin L. The INK4a/AKF locus and melanoma. Oncogene 2003;22:3092-8.
9. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996;85:27-37.
10. Sviderskaya EV, Hill SP, Evans-Whipp TJ, et al. p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 2002;94:446-54.
11. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997;11:2822-34.
12. Sviderskaya EV, Gray-Schopfer VC, Hill SP, et al. p16/Cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 2003;95:723-32.
13. Smith J. T-box genes: what they do and how they do it. Trends Genet 1999;15:154-8.
14. Tada M, Smith JC. T-targets: clues to understanding the functions of T-box proteins. Dev Growth Differ 2001;43:1-11.
15. Papaioannou VE. T-box genes in development: from hydra to humans. Int Rev Cytol 2001;207:1-70.
16. Papaioannou VE, Silver LM. The T-box gene family. BioEssays 1998;20:9-19.
17. Law DJ, Gebuhr T, Garvey N, Agulnik SI, Silver LM. Identification, characterization, and localization to chromosome 17q21-22 of the human TBX2 homolog, member of a conserved developmental gene family. Mamm Genome 1995;6:793-7.
18. Campbell C, Goodrich K, Casey G, Beatty B. Cloning and mapping of a human gene (TBX2) sharing a highly conserved protein motif with the Drosophila omb gene. Genomics 1995;28:255-60.
19. Mahlamaki EH, Barlund M, Tanner M, et al. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer 2002;35:353-8.
20. Sinclair CS, Adem C, Naderi A, et al. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Res 2002;62:3587-91.
21. Fan W, Huang X, Chen C, Gray J, Huang T. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. Cancer Res 2004;64:5132-9.
22. Carlson H, Ota S, Song Y, Chen Y, Hurlin PJ. Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation. Oncogene 2002;21:3827-35.
23. Prince S, Carreira S, Vance KW, Abrahams A, Goding CR. Tbx2 directly represses the expression of the p21(WAF1) cyclin-dependent kinase inhibitor. Cancer Res 2004;64:1669-74.
24. Jacobs JJ, Keblusek P, Robanus-Maandag E, et al. Senescence bypass screen identifies TBX2, which represses cdkn2a (p19ARF) and is amplified in a subset of human breast cancers. Nat Genet 2000;26:291-9.
25. Lingbeek ME, Jacobs JJ, van Lohuizen M. The T-box repressors TBX2 and TBX3 specifically regulate the tumor suppressor gene p14ARF via a variant T-site in the initiator. J Biol Chem 2002;277:26120-7.
26. Brummelkamp TR, Kortlever RM, Lingbeek M, et al. TBX-3, the gene mutated in ulnar-mammary syndrome, is a negative regulator of p19ARF and inhibits senescence. J Biol Chem 2002;277:6567-72.
27. Carlson H, Ota S, Campbell CE, Hurlin PJ. A dominant repression domain in Tbx3 mediates transcriptional repression and cell immortalization: relevance to mutations in Tbx3 that cause ulnar-mammary syndrome. Hum Mol Genet 2001;10:2403-13.
28. Aksan I, Goding CR. Targeting the microphthalmia basic helix-loop-helix-leucine zipper transcription factor to a subset of E-box elements in vitro and in vivo. Mol Cell Biol 1998;18:6930-8.
29. Yavuzer U, Keenan E, Lowings P, Vachtenhein J, Currie G, Goding CR. The microphthalmia gene product interacts with the retinoblastoma protein in vitro and is a target for deregulation of melanocyte-specific transcription. Oncogene 1995;10:123-34.
30. Lechner T, Lusser A, Brosch G, Eberharter A, Goralik-Schramel M, Loidl P. A comparative study of histone deacetylases of plant, fungal and vertebrate cells. Biochim Biophys Acta 1996;1296:181-8.
31. Galibert MD, Carreira S, Goding CR. The Usf-1 transcription factor is a novel target for the stress-responsive p38 kinase and mediates UV-induced tyrosinase expression. EMBO J 2001;20:5022-31.
32. Carreira S, Liu B, Goding CR. The gene encoding the T-box transcription factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J Biol Chem 2000;275:21920-7.
33. Wang E, Panelli MC, Zavaglia K, et al. Melanoma-restricted genes. J Transl Med 2004;2:34.
34. Carreira S, Dexter TJ, Yavuzer U, Easty DJ, Goding CR. Brachyury-related transcription factor Tbx2 and repression of the melanocyte-specific TRP-1 promoter. Mol Cell Biol 1998;18:5099-108.
35. Paxton C, Zhao H, Chin Y, Langner K, Reecy J. Murine Tbx2 contains domains that activate and repress gene transcription. Gene 2002;283:117-24.
36. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:81-120.
37. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49.
38. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9:40-8.
39. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG. Histone acetylation and the cell-cycle in cancer. Front Biosci 2001;6:D610-29.
40. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol 2003;3:344-51.
41. Medina V, Edmonds B, Young GP, James R, Appleton Zalewski P. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997; 57:3697-707.
42. 2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000;11:2069-83.
43. Sambucetti LC, Fischer DD, Zabludoff S, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999;274:34940-7.
44. Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene 2004;23:2347-56.
45. Rallis C, Bruneau BG, Del Buono, et al. Tbx5 is required for forelimb bud formation and continued outgrowth. Development 2003;130:2741-51.
46. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995;23:1686-90.
47. Rice JC, Allis CD. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol 2001;13:263-73.
48. Brenner S, Pepper D, Berns MW, Tan E, Brinkley BR. Kinetochore structure, duplication, and distribution in mammalian cells: analysis by human autoantibodies from scleroderma patients. J Cell Biol 1981;91:95-102.
49. Bennett DC, Medrano EE. Molecular regulation of melanocyte senescence. Pigment Cell Res 2002;15:242-50.
50. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci 1998;23:291-6.
51. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
52. Archer SY, Meng S. Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 1998;95:6791-6.
53. Sowa Y, Orita T, Minamikawa S, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997;241:142-50.
54. Janson W, Brandner G, Siegel J. Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis. Oncogene 1997;15:1395-406.
55. Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, Grant S. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol 2001;19:181-91.
56. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip gene promoter by histone deacetylase inhibitor. Cancer Res 1999;59:4266-70.
57. Nakano K, Mizuno T, Sowa Y, et al. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 1997;272:22199-206.
58. Dehm SM, Hilton TL, Wang EH, Bonham K. SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors. Mol Cell Biol 2004;24:2296-307.
59. Lagger G, O'Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002;21:2672-81.
60. Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocyte to melanomas. Cancer Res 2004;64:5270-82.
61. Hiroi Y, Kudoh S, Monzen K, et al. Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation. Nat Genet 2001;28:276-80.
62. Ghosh TK, Packham EA, Bonser AJ, Robinson TE, Cross SJ, Brook JD. Characterization of the TBX5 binding site and analysis of mutations that cause Holt-Oram syndrome. Hum Mol Genet 2001;10:1983-94.
63. Kispert A, Koschorz B, Herrmann BG. The T protein encoded by Brachyury is a tissue-specific transcription factor. EMBO J 1995;14:4763-72.
64. Hatcher CJ, Kim MS, Mah CS, et al. TBX5 transcription factor regulates cell proliferation during cardiogenesis. Dev Biol 2001;230:177-88.